Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486219 | 0.99 | LMNA (0.48) | LMNAMAPTCA1CA2 | |
| SCHEMBL6688943 | 0.98 | LMNA (0.49) | LMNAMAPTCA1CA2CYP1A2 | |
| SCHEMBL6895029 | 0.95 | LMNA (0.51) | LMNAMAPTCA1CA2CYP1A2 | |
| SCHEMBL21331281 | 0.84 | LMNA (0.46) | LMNAMAPTCA1CA2CYP1A2 | |
| SCHEMBL3192 | 0.83 | DDB1 (0.51) | LMNACA1CA2 | |
| SCHEMBL551405 | 0.82 | DDB1 (0.50) | LMNACA1CA2 | |
| Hydrochloric Acid SCHEMBL1809434 | 0.82 | DDB1 (0.50) | LMNACA1CA2 | |
| SCHEMBL1841706 | 0.82 | DDB1 (0.50) | LMNACA1CA2 | |
| Hydrochloric Acid SCHEMBL7530629 | 0.81 | DDB1 (0.49) | LMNA | |
| SCHEMBL1144346 | 0.81 | DDB1 (0.51) | LMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3176478-A | — | — | None | — | — | JP | disclosed |
| US-20190105409-A9 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | GE HEALTHCARE AS (NO) | 2019-04-11 | — | — | US | disclosed |
| US-20140286866-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | GE HEALTHCARE AS (NO) | 2014-09-25 | — | — | US | disclosed |
| US-20120269727-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | GE HEALTHCARE AS (NO) | 2012-10-25 | — | — | US | disclosed |
| US-20080095704-A1 | A polyoxyethylene glycol having a molecular weight of < 3000 Da and 2-50 ethylene glycol units, an imageable moiety anda non-peptidic vector moiety provided that the vector does not have affinity for the Angiotensin II receptor; enhanced contrast; tomography (SPECT); PET sccans; MRIs | GE HEALTHCARE AS (NO) | 2008-04-24 | — | — | US | disclosed |
| EP-1682113-B1 | INHIBITOR IMAGING AGENTS | GE HEALTHCARE LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20070104644-A1 | Inhibitor imaging agents | CUTHBERTSON ALAN | 2007-05-10 | — | — | US | disclosed |
| EP-1415984-A1 | Aryloxyarylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| EP-1003720-B1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6214872-B1 | ANTIARTHRITIC AND ANTICARCINOGENIC AGENTS | PFIZER INC. | 2001-04-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
| US-6107337-A | ANTIARTHRITIC AGENTS; ANTICARCINOGENIC AGENTS | PFIZER INC. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0895988-A1 | Arylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 1999-02-10 | — | — | EP | disclosed |
| EP-0333000-B1 | PEPTIDES WITH INHIBITORY ACTIVITY OF ENZYMATIC SYSTEMS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZAMBON GROUP S.p.A. (IT) | 1993-05-19 | — | — | EP | disclosed |
| US-5145872-A | PEPTIDES WITH PHARMACEUTICAL ACTIVITY | ZAMBON GROUP, S.P.A. (IT) | 1992-09-08 | — | — | US | disclosed |
| JP-H03176478-A | NEW DIKETOPIPERAZINE DERIVATIVE AND IMMUNOSUPPRESSIVE AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | SNOW BRAND MILK PROD CO LTD | 1991-07-31 | — | — | JP | disclosed |
| EP-0333000-A2 | Peptides with inhibitory activity of enzymatic systems, process for their preparation and pharmaceutical compositions containing them | ZAMBON GROUP S.p.A. (IT) | 1989-09-20 | — | — | EP | disclosed |
| EP-0036713-B1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | UNIVERSITY OF MIAMI (US) | 1984-01-18 | — | — | EP | disclosed |
| EP-0036713-A2 | Angiotensin converting enzyme inhibitors | UNIVERSITY OF MIAMI (US) | 1981-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080095704-A1 | A polyoxyethylene glycol having a molecular weight of < 3000 Da and 2-50 ethylene glycol units, an imageable moiety anda non-peptidic vector moiety provided that the vector does not have affinity for the Angiotensin II receptor; enhanced contrast; tomography (SPECT); PET sccans; MRIs | AGTR1, AGTR2, AVPR1A | LMNA 2967/4885MAPT 784/4885CA1 1424/4885 |
| US-20190105409-A9 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | SLC10A1, SLC10A2, SLC19A1 | LMNA 3758/4885MAPT 1046/4885CA1 3092/4885 |
| US-20140286866-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | SLC10A1, SLC10A2, SLC19A1 | LMNA 3758/4885MAPT 1046/4885CA1 3092/4885 |
| US-20120269727-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | SLC10A1, SLC10A2, SLC19A1 | LMNA 3758/4885MAPT 1046/4885CA1 3092/4885 |
| US-20070104644-A1 | Inhibitor imaging agents | MMP3, MMP1, MMP10 | LMNA 2484/4885MAPT 1990/4885CA1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.